Paul Tudor Jones Supernus Pharmaceuticals, Inc. Transaction History

Tudor Investment Corp Et Al

$26.8 Billion
Q3 2024

A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 27,525 shares of SUPN stock, worth $979,890. This represents 0.0% of its overall portfolio holdings.

Number of Shares

27,525

Holding current value

$979,890

% of portfolio

0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$25.77 - $35.16 $709,319 - $967,778	27,525 New	27,525 $858,000
Q2 2023 Aug 14, 2023	SELL	$29.91 - $38.73 $482,657 - $624,986	-16,137 Reduced 36.75%	27,769 $834,000
Q1 2023 May 15, 2023	SELL	$34.93 - $42.03 $1.29 Million - $1.55 Million	-36,801 Reduced 45.6%	43,906 $1.59 Million
Q4 2022 Feb 14, 2023	SELL	$31.09 - $37.88 $343,544 - $418,574	-11,050 Reduced 12.04%	80,707 $2.88 Million
Q3 2022 Nov 14, 2022	SELL	$28.79 - $35.41 $559,274 - $687,874	-19,426 Reduced 17.47%	91,757 $3.11 Million
Q2 2022 Aug 15, 2022	SELL	$25.33 - $34.25 $427,925 - $578,619	-16,894 Reduced 13.19%	111,183 $3.22 Million
Q1 2022 May 16, 2022	BUY	$28.51 - $32.9 $1.2 Million - $1.38 Million	41,964 Added 48.73%	128,077 $4.14 Million
Q4 2021 Feb 14, 2022	BUY	$26.37 - $34.22 $461,896 - $599,397	17,516 Added 25.53%	86,113 $2.51 Million
Q3 2021 Nov 15, 2021	BUY	$23.54 - $31.39 $1.36 Million - $1.81 Million	57,797 Added 535.16%	68,597 $1.83 Million
Q2 2021 Aug 16, 2021	SELL	$26.72 - $33.19 $917,270 - $1.14 Million	-34,329 Reduced 76.07%	10,800 $333,000
Q1 2021 May 17, 2021	BUY	$24.15 - $31.45 $1.09 Million - $1.42 Million	45,129 New	45,129 $1.18 Million
Q2 2020 Aug 14, 2020	SELL	$17.09 - $24.89 $506,205 - $737,241	-29,620 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$14.45 - $24.69 $196,910 - $336,450	-13,627 Reduced 31.51%	29,620 $533,000
Q4 2019 Feb 14, 2020	BUY	$19.93 - $29.13 $158,483 - $231,641	7,952 Added 22.53%	43,247 $1.03 Million
Q3 2019 Nov 14, 2019	SELL	$25.47 - $33.37 $279,405 - $366,068	-10,970 Reduced 23.71%	35,295 $970,000
Q2 2019 Aug 14, 2019	BUY	$29.96 - $38.87 $143,328 - $185,954	4,784 Added 11.53%	46,265 $1.53 Million
Q1 2019 May 15, 2019	BUY	$32.77 - $41.99 $188,886 - $242,030	5,764 Added 16.14%	41,481 $1.45 Million
Q4 2018 Feb 14, 2019	BUY	$30.84 - $49.51 $1.1 Million - $1.77 Million	35,717 New	35,717 $1.19 Million

Others Institutions Holding SUPN

# of Institutions

281

Shares Held

60.6M

Call Options Held

27.7K

Put Options Held

11.3K

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.9B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track Paul Tudor Jones's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Account